Faculty Summaries
Gary R Hudes, MD
Gary R Hudes, MD
Professor

2010

  • Ibragimova I, de Caceres, Hoffman AM, Potapova A, Dulaimi E, Al-Saleem T, Hudes GR, Ochs MF, Cairns P. Global Reactivation of Epigenetically Silenced Genes in Prostate Cancer. Cancer Prevention Research. 2010 Sep;3(9):1084-92.
  • Pei J, Feder MM, Al-Saleem T, Liu Z, Liu A, Hudes GR, Uzzo RG, Testa JR. Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma. Genes Chromosomes Cancer. 2010 Jul;49(7):610-9.
  • Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG. Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology-Cancer Clinical Trials. 2010 Dec;33(6):614-8.
  • Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, Wang LS, Tran-Thanh D, Pham NA, Tsao MS, Hedley D, Dancey JE, Moore MJ. A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer. American Journal of Clinical Oncology-Cancer Clinical Trials. 2010 Dec;33(6):609-13.
  • Zbrozek AS, Hudes G, Levy D, Strahs A, Berkenblit A, DeMarinis R, Parasuraman S. Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma. Pharmacoeconomics. 2010;28(7):577-84.
Top

2009

  • Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Hudes G. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009;26(2):202-9.
  • Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. J Clin Oncol. 2009 Sep;27(27):4462-8.
  • Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer. 2009 Apr 28;115(S10):2313-20.
  • Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer. J Clin Oncol. 2009 Jan;27(1):100-5.
  • Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabro F, Cheng ST, Trudel GC, Paliwal P, Sternberg CN. Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2009 Dec;15(23):7421-8.
  • Garcia JA, Hudes G, Choueiri TK, Stadler WM, Wood L, Bhatia S, Youssoufian H, Rowinsky EK, Schwartz JD, Thompson JA. Phase II study of IMC-1121B in patients with metastatic renal cell carcinoma (mRCC) following failure of VEGFR-2 tyrosine kinase inhibitor (TKI) therapy: interim results (IMCL CP12-0605/NCT00515697). EJC Supplements. 2009 Sep;7(2):425.
  • Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G. Analysis of PTEN and HIF-1 alpha and Correlation With Efficacy in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus Versus Interferon-alpha. Cancer. 2009 Aug;115(16):3651-60.
  • Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol. 2009 Dec;36 Suppl 3:S26-36.
  • Pablo M, Hudes G, Dutcher J, White C, Krygowski M, Cincotta M, Ohata J, Duran I, Berkenblit A. Radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced renal cell carcinoma treated with temsirolimus. EJC Supplements. 2009 Sep;7(2):426-7.
  • Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L. Innovations and Challenges in Renal Cancer: Summary Statement From the Third Cambridge Conference. Cancer. 2009;115(10):2247-51.
  • Yang S, Hudes G, deSouza P, Alemao E, Strahs A, Purvis J. Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial. EJC Supplements. 2009 Sep;7(2):433.
  • Hudes GR. Targeting mTOR in Renal Cell Carcinoma. Cancer. 2009 May 15;115(10 Suppl):2313-20.
Top

2008

  • Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-S20; quiz S21-S22.
  • Trask PC, Mardekian J, Tarazi J, Bycott P, Kim S, Dutcher JP, Wilding G, Hudes GR, Stadler WM, Rini B. Disease related symptoms of kidney cancer in sorafenib-refractory metastatic renal cell cancer (MRCC) patients (PTS) treated with axitinib. (AG-013736). Ann Oncol. 2008;19:192.
  • De Bono JS, Petrylak DP, Calvo E, Saad F, Hudes GR, Cooney MM, Pollak MN, Agus DB, Gillessen S, Scranton J. Activity of the anti-IGF-IR antibody CP-751,871 in combinatiion with docetaxel as first-line treatment for castration resistant prostate cancer in a randomized Phase II trial. 2008;:178.
Top

2007

  • Beer TM, Higano CS, Saleh M, Dreicer R, Hudes G, Picus J, Rarick M, Fehrenbacher L, Hannah AL. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs. 2007 Dec;25(6):565-70.
  • Houk BE, Bello CL, Michaelson MD, Bukowski RM, Redman B, Hudes GR, Wilding G, Motzer RJ. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure-response for sunitinib in metastatic renal cell carcinoma (mRCC). EJC Supplements. 2007 Sep;5(4):300.
  • Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol. 2007 Sep;25(25):3958-64.
  • Hudes G. Temsirolimus for advanced renal-cell carcinoma - Reply. N Engl J Med. 2007 Sep;357(10):1050-1.
  • Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 May 31;356(22):2271-81.
  • George DJ, Michaelson MD, Rosenberg JE, Redman BG, Hudes GR, Bukowski RM, Kim ST, Chen I, Wilding G, Motzer RJ. Sunitinib in patients with cytokine-refiractory metastatic renal cell carcinoma (mRCC). EJC Supplements. 2007 Sep;5(4):304.
  • Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymord JC, Logothetis CJ, Pignon JP, Michiels S. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol. 2007 Nov;8(11):994-1000. Epub 2007 Oct 17. 2007 Nov;8(11):994-1000.
  • Hudes GR. mTOR as a Target for Therapy of Renal Cancer. Clin Adv Hematol Oncol. 2007 Oct;5(10):772-4.
  • Kondagunta GV, Hudes G, Figlin R, Wilding G, Hariharan S, Kempin S, Fayyad R, Hoosen S, Motzer RJ. Sunitinib plus interferon-alfa in the first-line treatment for metastatic renal cell carcinoma (mRCC): results of a dose-finding study. EJC Supplements. 2007 Sep;5(4):305.
  • Mallick R, Hudes G, Levy DE. Clinically important difference in quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-A (IFN). Value in Health. 2007 Nov-Dec;10(6):A342-A342.
  • Mallick R, Sun S, Hudes G. Patient-reported impairment of EuroQol health states and preference-weighted utility in advanced renal cell carcinoma in a recent clinical trial. Value in Health. 2007 Nov-Dec;10(6):A344-A344.
  • Litwin S, Wong YN, Hudes G. Early stopping designs based on progression-free survival at an early time point in the initial cohort. Stat Med. 2007 Oct 30;26(24):4400-15.
  • De Souza P, Maart K, Laurell A, Hawkins RE, Berkenblit A, Galand L, Thiele A, Strahs A, Feingold J, Hudes G. Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon-alpha or the combination of temsirolimus plus interferon-alpha. EJC Supplements. 2007 Sep;5(4):282-3.
  • Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007 Nov;178(5):1883-7.
  • Wong YN, Mitra N, Hudes G, Schwartz JS, Wan F, Montagnet C, Armstrong K. Outcomes of treatment vs observation of localized prostate cancer in elderly men - Reply. JAMA-Journal of the American Medical Association. 2007 Apr;297(15):1652-3.
  • Tolcher AW, Karavasilis V, Hudes G, Quinn D, Ferrari A, Kocak I, Mita A, Buell D, Keating A, Bartels P, Charleston D, DeBono J. YM155, a novel survivin suppressant, demonstrates activity in subjects with hormone refractory prostate cancer (HRPC) previously treated with taxane chemotherapy. Ann Oncol. 2007;18:39.
  • Redman BG, Hudes GR, Kondagunta GV, Patel PH, Kim ST, Chen I, Motzer RJ. Phase 1/2 study of sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). EJC Supplements. 2007 Sep;5(4):302.
  • Rini B, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Bycott P, Liau K, Dutcher J. Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib. EJC Supplements. 2007 Sep;5(4):300.
  • Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liou KF, Freddo J, Trask PC, Kim S, Rini BI. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007 Nov;8(11):975-84.
Top

2006

  • McDermott RS, Kloth DD, Wang H, Hudes GR, Langer CJ. Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model. J Support Oncol. 2006 Nov-Dec;4(10):524-9.
  • Houk BE, Amantea M, Motzer RJ, Michaelson MD, Rini BI, George DJ, Redman BG, Hudes GR, Poland B, Bello CL. Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2006 Jun;24(18):224S-224S.
  • Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, Lewis N, Weiner L, Lam GN, Brown SC, Shaw DE, Mazar AP, Cohen RB. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. Br J Cancer. 2006 Jun;94(11):1621-6.
  • Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jan 1;24(1):16-24.
  • Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2006 Jun;295(21):2516-24.
  • Wong YN, Mitra N, Hudes G, Localio R, Schwartz JS, Wan F, Montagnet C, Armstrong K. Survival associated with treatment vs observation of localized prostate cancer in elderly men.[see comment]. JAMA. 2006 Dec 13;296(22):2683-93.
  • Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, O'Toole T, Park Y, Moore L. A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR plus IFN in the treatment of first-line, poor-prognosis patients with advanced renal cell carcinoma. J Clin Oncol. 2006 Jun;24(18):2S-2S.
  • Hudes G, Carducci M, Tomczak P, Duther J, Figlin R, Kapoor A, Staroslawska E, O'Toole T, Park Y, Moore L. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR plus IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (ADV RCC). Ann Oncol. 2006;17:54.
  • Fizazi K, Hudes GR, Berry WR, Kelly WK, Eymard JC, Logothetis C, Le Maitre A, Pignon JP, Michiels S. A meta-analysis of individual patient data from randomized trials assessing chemotherapy with and without estramustine in patients with castration-refractory prostate cancer. J Clin Oncol. 2006 Jun;24(18):231S-231S.
  • Haas NB, Lewis N, Cohen RB, Malizzia L, Einarson MB, Walker MA, Kim T, Von Mehren M, Hudes GR. Phase I study of intravenous CCI-779 in combination with bryostatin-1 in solid tumors. J Clin Oncol. 2006 Jun;24(18):137S-137S.
  • Burris HA, Hudes G, Jones S, Cheng J, Spigel D, Mariani M, Macdonald H, Rocchetti M, Laffranchi B, Cohen RB. Phase I dose escalation study of the Aurora kinase inhibitor PHA-739358 administered as a 24 hours infusion in a 14-day cycle in patients with advanced/metastatic solid tumor. EJC Supplements. 2006 Nov;4(12):107.
Top

2005

  • Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. New paradigm in dose-finding trials: Patient-specific dosing and beyond phase I. Clin Cancer Res. 2005 Aug 1;11(15):5342-6.
  • Motzer R, Rini B, Michaelson M, Redman B, Hudes G, Wilding I, Bukowski R, George D, Kim S, Baum C. Sunitinib malate (SU11248) shows antitumour activity in patients with metastatic renal cell carcinoma: updated results from phase II trials. EJC Supplements. 2005 Oct;3(2):227.
  • Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Bukowski RM, George DJ, Kim ST, Baum CM. Phase 2 trials of SU1 1248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol. 2005 Part 1 Suppl. S JUN 1;23(16):380S-380S.
  • Thomas G, Speicher L, Reiter R, Ranganathan S, Hudes G, Strahs A, Pisters L, Greenberg R, Ryan J, Logothetis C, Sawyers C. Demonstration that temsirolimus preferentially inhibits the mTOR pathway in the tumors of prostate cancer patients with PTEN deficiencies. Clin Cancer Res. 2005 Part;11(24):9132S-9132S.
  • Hudes GR. Temsirolimus (CCI-779): Early results of an mTOR inhibitor in renal carcinoma. Ann Oncol. 2005 Suppl. 3;16:18.
  • Hudes GR, Celano P, Torti F, Tabatabai A, Murgo A, Hussain A. Phase II study of weekly paclitaxel (PAC) and bryostatin-1 (BRYO) in hormone refractory prostate cancer (HRPC). J Clin Oncol. 2005 Part 1 Suppl. S JUN 1;23(16):431S-431S.
  • Simons JW, Higano C, Smith D, Corman J, Steidle C, Gittelman M, Hudes G, Aimi J, Sacks N, Small E. Clinical and immunologic findings in a phase 2 study of a GM-CSF-secreting prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (met HPRC). J Clin Oncol. 2005 Part 1 Suppl. S JUN 1;23(16):170S-170S.
  • Burczynski ME, Twine NC, Dukart G, Marshall B, Hidalgo M, Stadler WM, Logan T, Dutcher J, Hudes G, Trepicchio WL, Strahs A, Immermann F, Slonim DK, Dorner AJ. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res. 2005 Feb 1;11(3):1181-9.
  • Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, Bolte O, Steinfeldt H, Reich SD, Motzer R. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol. 2005 Part 1 Suppl. S JUN 1;23(16):380S-380S.
Top

2004

  • McDermott RS, Anderson PR, Greenberg RE, Milestone BN, Hudes GR. Cranial nerve deficits in patients with metastatic prostate carcinoma - Clinical features and treatment outcomes. Cancer. 2004 Oct 1;101(7):1639-43.
  • Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium - A trial of the eastern cooperative oncology group. Cancer. 2004 Apr;100(8):1639-45.
  • Hudes G, Menon S, Golemis E. Protein interaction-targeted drug discovery. In: Rapley MR, Harbron S, editors. Molecular Analysis and Genome Discovery. Hoboken, NJ: John Wiley & Sons; 2004. p. 325-47.
  • Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Lion SH, Marshall B, Boni JP, Dukart G, Sherman ML. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004 Mar;22(5):909-18.
  • Rogatko A, Babb JS, Wang H, Slifker MJ, Hudes GR. Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin Cancer Res. 2004 Jul;10(14):4645-51.
  • McDermott RS, Meropol NJ, Weiner LM, Yeslow G, Hudes GR. Phase I clinical and pharmacokinetic study of the farnesyl transferase inhibitor BMS-214662 administered intravenously for five consecutive days in patients with advanced malignancies. J Clin Oncol. 2004 2033 Suppl. S JUL 15;22(14):135S-135S.
  • Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Zhu J, Kim ST, Baum C. SUO11248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. J Clin Oncol. 2004 4500 Suppl. S JUL 15;22(14):382S-382S.
  • Wong Y, Sherman E, Hudes G, Haas N, Konski A, Uzzo R, Greenberg R, Beck R. Modeling the cost-effectiveness of treatment options for patients with clinical stage I non seminomatous germ cell tumors (NGSCT). J Clin Oncol. 2004 4525 Suppl. S JUL 15;22(14):388S-388S.
  • Mueller TJ, Wu H, Greenberg RE, Hudes G, Topham N, Lessin SR, Uzzo RG. Cutaneous metastases from genitourinary malignancies. Urology. 2004 Jun;63(6):1021-6.
  • Small E, Higano C, Smith D, Corman J, Centeno A, Steidle C, Gittelman M, Hudes G, Sacks N, Simons J. A phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (HRPC). J Clin Oncol. 2004 4565 Suppl. S JUL 15;22(14):398S-398S.
  • Smith JW, Ko YJ, Dutcher J, Hudes G, Escudier B, Motzer R, Negrier S, Duclos B, Galand L, Strauss L. Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-alpha to patients with advanced renal cell carcinoma. J Clin Oncol. 2004 4513 Suppl. S JUL 15;22(14):385S-385S.
Top

2003

  • McDermott R, Hudes GR. Commentary: "Testis cancer: maintaining the high cure rate" by Derek Raghavan. Oncology. 2003;17:234-5.
  • Hudes GR. Boosting bioavailability to topotecan: What do we gain? Reply. J Clin Oncol. 2003 Jan;21(1):177.
  • Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003 Apr 1;21(7):1301-6.
  • David A, Khwaja R, Hudes G. Treatments for improving survival of patients with prostate cancer. Drugs Aging. 2003;20(9):683-99.
  • Haas NB, Giantonio BJ, Litwin S, Minniti CJ, Fox S, Yeslow G, Reilly R, Nahum K, Greenberg R, Halbherr T, Hudes GR. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma - A phase II trial of the fox chase network. Cancer. 2003 Nov;98(9):1837-41.
  • Haas NB, Smith M, Lewis N, Littman L, Yeslow G, Joshi ID, Murgo A, Bradley J, Gordon R, Wang H, Rogatko A, Hudes GR. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study. Clin Cancer Res. 2003 Jan;9(1):109-14.
  • Twine NC, Stover JA, Marshall B, Dukart G, Hidalgo M, Stadler W, Logan T, Dutcher J, Hudes G, Dorner AJ, Slonim DK, Trepicchio WL, Burczynski ME. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res. 2003 Sep;63(18):6069-75.
  • Uzzo RG, Cairns P, Al-Saleem T, Hudes G, Haas N, Greenberg RE, Kolenko V. The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. Urol Clin North Am. 2003 Aug;30(3):423-36.
Top

2002

  • Hudes G. Boosting bioavailability of topotecan: what do we gain?. J Clin Oncol. 2002 Jul 1;20(13):2918-9.
  • Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, Nordle O, Eriksson B, Miller L, Cisar L, Kopreski M, Viaro D, Hartley-Asp B. Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. J Clin Oncol. 2002 Feb 15;20(4):1115-27.
  • Movsas B, Hudes G, Olsson CA. Atlas of genitourinary oncology. Philadelphia: Saunders; 2002.
  • Hudes GR. Signaling inhibitors in the treatment of prostate cancer. Invest New Drugs. 2002 May;20(2):159-72.
  • Hudes GR, Saxman S. Nonseminomatous germ cell tumors: systemic issues. In: Movsas B, Hudes G, Olsson CA, editors. Atlas of genitourinary oncology. Philadelphia: Saunders; 2002. p. 199-204.
  • Schulsinger A, Ramesh V, Rotman M, Hudes G. Bladder cancer: radiotherapy and chemotherapy. In: Movsas B, Hudes G, Olsson CA, editors. Atlas of genitourinary oncology. Philadelphia: Saunders; 2002. p. 95-115.
Top

2001

  • Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am. 2001 Jun;15(3):525-45.
  • Obasaju C, Manola J, Hudes GR, Khandekar JD, Citrin DL, Carbone P, Trump DL. Phase II evaluation of menogaril in advanced prostate cancer: Eastern Cooperative Oncology Group EST P-A885. Am J Clin Oncol. 2001 Apr;24(2):150-4.
  • Hudes GR, Schol J. Phase I trial of oral R115777 in patients with refractory solid tumors: preliminary results. In: Sebti SM, Hamilton AD, editors. Farnesyltransferase inhibitors in cancer therapy. Totowa, N.J.: Humana Press; 2001. p. 251-4.
  • Giantonio BJ, Hochster H, Blum R, Wiernik PH, Hudes GR, Kirkwood J, Trump D, Oken MM. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs. 2001;19(1):89-92.
  • Ranganathan S, McCauley RA, Dexter DW, Hudes GR. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells. Br J Cancer. 2001 Sep 1;85(5):735-40.
  • Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, Rogatko A, Babb J, Minnitti C, Flinker D, Gillon T, Hudes G. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology. 2001 Jul;58(1):59-64.
Top

2000

  • Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M. Phase II study of dolastatin-10 in patients with hormone- refractory metastatic prostate adenocarcinoma. Clin Cancer Res. 2000 Nov;6(11):4205-8.
  • Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr T, Qian M, Gallo JM. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res. 2000 Aug;6(8):3071-80.
  • Haas NB, Manola J, Hudes G, Citrin DL, Kies MS, Davis TE. Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer. Am J Clin Oncol. 2000 Dec;23(6):589-92.
Top